Valuation: Control Bionics Limited

Market Cap 30.49M 21.32M 18.72M 17.41M 15.98M 30.02M 2.05B 207M 80.78M 1.01B 80.03M 78.3M 3.49B P/E 2024
-1.4x
P/E 2025 -1.3x
Enterprise Value 30.25M 21.15M 18.58M 17.28M 15.85M 29.79M 2.04B 205M 80.15M 1B 79.41M 77.69M 3.46B EV / Sales 2024
1.92x
EV / Sales 2025 1.4x
Free-Float
55.4%
Yield 2024 *
-
Yield 2025 -
1 day+7.81%
1 week-1.43%
Current month-6.76%
1 month-20.69%
3 months+15.00%
Current year+13.11%
1 week 0.06
Extreme 0.064
0.07
1 month 0.06
Extreme 0.064
0.09
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.74
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 19/01/2023
Director of Finance/CFO - 13/05/2024
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman - 01/12/2025
Chairman 66 19/11/2025
Director/Board Member - 19/01/2023
Change 5-day change 1-year change 3-year change Capi.($)
+7.81%-1.43%+81.58%-23.33% 19.87M
-0.36%-10.53%+15.40%-36.86% 15.63B
-7.90%-1.58%+0.67%+98.26% 1.79B
-3.20%-7.65%-39.04%-81.82% 1.13B
-1.41%-5.94%-38.80%+9.08% 960M
-3.39%-9.44%-31.96%-55.49% 630M
-2.46%-12.40%-49.22%-57.99% 517M
+1.87%+3.51%+44.64%-52.83% 452M
+1.52%-5.19%-56.07%-62.31% 359M
+0.72%+2.49%-21.26%-38.86% 339M
Average -1.02%-4.30%-9.41%-30.22% 2.18B
Weighted average by Cap. -1.74%-8.03%+5.01%-27.91%

Financials

2024 2025
Net sales 5.35M 3.74M 3.29M 3.06M 2.8M 5.27M 360M 36.29M 14.18M 177M 14.05M 13.74M 613M 6.14M 4.3M 3.77M 3.51M 3.22M 6.05M 414M 41.68M 16.28M 203M 16.13M 15.78M 703M
Net income -5.91M -4.14M -3.63M -3.38M -3.1M -5.82M -398M -40.11M -15.67M -196M -15.52M -15.19M -677M -6.11M -4.27M -3.75M -3.49M -3.2M -6.02M -411M -41.43M -16.19M -202M -16.04M -15.69M -699M
Net Debt -96.95K -67.79K -59.54K -55.37K -50.81K -95.47K -6.53M -658K -257K -3.21M -255K -249K -11.1M -237K -166K -146K -136K -124K -234K -15.98M -1.61M -629K -7.86M -623K -609K -27.16M
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
24/07/26 A$0.0690 +7.81% 39,210
23/07/26 A$0.0640 -8.57% 238,405
22/07/26 A$0.0700 +6.06% 19,245
21/07/26 A$0.0660 -2.94% 544,067
20/07/26 A$0.0680 -1.45% 221,044

Annual profits - Rate of surprise